HRTX

Heron Therapeutics, Inc.$0.41+0.00 (+0.26%)

Prev Close$0.41·MCap$144.4M·P/E—·Vol3.93M·Yield—

▲

Buys (12M)

$2.65M

▼

Sells (12M)

$0.00

◆

Net Activity

Net Buyer

$2.65M

●

Active Insiders

last 12 mo

Over the past 12 months, insider activity at Heron Therapeutics, Inc. (HRTX) has been exclusively buying, with 1 insider purchase totaling $2.65M and 0 insider sales totaling $0.00. The most recent insider transaction was by Morgan Adam (Director), who purchased $2.65M worth of shares on Aug 8, 2025. Heron Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $144.4M.

HRTX Insider Trading Activity

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Aug 8, 2025	Morgan Adam	Director	Buy	1,766,546	$1.50	$2.65M1.1% OS	0
Nov 21, 2023	Forbes William P	EVP, Chief Development Officer	Buy	25,000	$1.09	$27.3K	79,000+46%
Nov 20, 2023	Forbes William P	EVP, Chief Development Officer	Buy	50,000	$0.94	$47.0K	54,000New Position
Nov 17, 2023	Collard Craig A	Chief Executive Officer	Buy	150,000	$0.92	$138.0K	186,496+411%
Nov 17, 2023	Duarte Ira	EVP, Chief Financial Officer	Buy	85,000	$0.89	$75.6K	85,000
Jul 25, 2023	Morgan Adam	Director	Buy	3,649,635	$1.37	$5.00M2.3% OS	6,986,744+109%
May 4, 2022	MANHARD KIMBERLY	EVP, Drug Development	Sell	1,504	$4.76	$7.2K	10,872
Dec 23, 2021	Christian Waage	Director	Sell	300	$9.73	$2.9K	3,200
Dec 23, 2021	Johnson Craig A	Director	Sell	250	$9.73	$2.4K	2,840
Sep 23, 2021	Christian Waage	Director	Sell	300	$12.31	$3.7K	3,500
Sep 23, 2021	Johnson Craig A	Director	Sell	250	$12.30	$3.1K	3,090
Jun 22, 2021	Christian Waage	Director	Sell	300	$15.20	$4.6K	3,800
Jun 22, 2021	Johnson Craig A	Director	Sell	250	$15.20	$3.8K	3,340
May 4, 2021	MANHARD KIMBERLY	EVP, Drug Development	Sell	1,529	$17.66	$27.0K	1,634-48%
Apr 16, 2021	Christian Waage	Director	Sell	300	$17.51	$5.3K	4,100
Apr 7, 2021	Johnson Craig A	Director	Sell	250	$17.22	$4.3K	3,590

HRTX Insider Buying Activity

The following table shows recent insider purchases of Heron Therapeutics, Inc. (HRTX) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
Aug 8, 2025	Morgan Adam	Director	Buy	1,766,546	$1.50	$2.65M1.1% OS	0
Nov 21, 2023	Forbes William P	EVP, Chief Development Officer	Buy	25,000	$1.09	$27.3K	79,000+46%
Nov 20, 2023	Forbes William P	EVP, Chief Development Officer	Buy	50,000	$0.94	$47.0K	54,000New Position
Nov 17, 2023	Collard Craig A	Chief Executive Officer	Buy	150,000	$0.92	$138.0K	186,496+411%
Nov 17, 2023	Duarte Ira	EVP, Chief Financial Officer	Buy	85,000	$0.89	$75.6K	85,000
Jul 25, 2023	Morgan Adam	Director	Buy	3,649,635	$1.37	$5.00M2.3% OS	6,986,744+109%

HRTX Insider Selling Activity

The following table shows recent insider sales of Heron Therapeutics, Inc. (HRTX) stock reported via SEC Form 4 filings.

Date	Insider	Role	Type	Shares	Avg Price	Value	Shares After
May 4, 2022	MANHARD KIMBERLY	EVP, Drug Development	Sell	1,504	$4.76	$7.2K	10,872
Dec 23, 2021	Christian Waage	Director	Sell	300	$9.73	$2.9K	3,200
Dec 23, 2021	Johnson Craig A	Director	Sell	250	$9.73	$2.4K	2,840
Sep 23, 2021	Christian Waage	Director	Sell	300	$12.31	$3.7K	3,500
Sep 23, 2021	Johnson Craig A	Director	Sell	250	$12.30	$3.1K	3,090
Jun 22, 2021	Christian Waage	Director	Sell	300	$15.20	$4.6K	3,800
Jun 22, 2021	Johnson Craig A	Director	Sell	250	$15.20	$3.8K	3,340
May 4, 2021	MANHARD KIMBERLY	EVP, Drug Development	Sell	1,529	$17.66	$27.0K	1,634-48%
Apr 16, 2021	Christian Waage	Director	Sell	300	$17.51	$5.3K	4,100
Apr 7, 2021	Johnson Craig A	Director	Sell	250	$17.22	$4.3K	3,590